- The Washington Times - Tuesday, August 9, 2005

DUBLIN (AP) — About 2,000 patients who took the suspended MS-fighting drug Tysabri in clinical trials have been screened for a deadly disease, but none showed signs of contracting it, the Irish and U.S. companies jointly developing the drug said yesterday.

Elan Corp. PLC of Dublin and Biogen Idec Inc. of Cambridge, Mass., said they were taking “preliminary steps” to resume clinical trials of Tysabri, which was withdrawn from the U.S. market on Feb. 28 amid fears its use could cause progressive multifocal leukoencephalopathy, or PML, a rare brain disease.

At the time, the companies said two multiple-sclerosis sufferers taking Tysabri had contracted PML, one fatally. They later confirmed a second fatal case of PML in a patient using Tysabri to treat Crohn’s disease, a gastrointestinal disorder.



Click to Read More

Click to Hide